is not always easy. If a client is 40 years of age and has an LDL chole sterol that exceeds 190 mg/dL, drug therapy might be delayed.
In general, drug therapy should be considered in older individuals (men > 45 years and women > 55 years) whose LDL level exceeds 190 mg/dL. A conscientious effort also must be made to determine any significant underlying genetic hyperlipidemias and a family history of premature coronary heart disease in younger adults. The goals of drug therapy in primary prevention are similar to those of diet-to lower the LDL cholesterol below 160 mg/dL, or below 130 mg/dL if two other risk factors are present.
For clients with established coronary heart disease, the decision is much easier. Many recent studies (Blankenhorn, 1987; Watts, 1992) show that progression of coronary heart disease may be decreased by aggressively lowering LDL cholesterol with diet and drug management. If LDL cholesterol is above 130 mg/dL, drug therapy should be considered. This therapy may even begin at the time of hospitalization for an acute coronary event if LDL cholesterol is above 130 mgldL. Most often, however, if clients try dietary measures for 3 months and LDL cholesterol remains above 130 mg/dL, drug therapy may be necessary. The goal for therapy in clients with established coronary heart disease is an LDL cholesterol level < 100 mg/dL. If an LDL cholesterol level remains in the range of 100 to 130 mg/dL, the decision to use drugs is based on the judgment of the health care provider.
Drug therapy for these clients will be life long. Health care professionals, therefore, must know the important factors that help clients establish a life long commitment to taking these drugs. The se include cost and convenience of the specified drug regimens, client preferences, and ability to manage side effects. Management al so must include a concerted effort to optimize drug therapy through weight loss , diet, and exercise .
CHOLESTEROL LOWERING DRUGS
The safety and short and long term efficacy of drugs were carefully reviewed by the Expert Panel developing the NCEP Guidelines. In this report, drugs are now classified as major and "other" (see Table 1 ). In post-menopausal women, estrogen replacement therapy is also considered a possible alternative or adjunct to drug therapy for those with elevated LDL-C cholesterol levels.
Major Drugs
Experience with the bile acid sequestrants within the Lipid Research Clinics Primary Prevention Trial (LRCP, 1984) indicates they are not only effective in reducing coronary heart disease risk, but they are also extremely safe drugs. They are particularly suita ble for treating younger clients, including women considering pregnancy, as they are not absorbed from the gastrointestinal tract and therefore lack systemic toxicity.
Both cholestyramine (Questr a n) and colestipol (Colestid) are considered the first choice of drugs within the new Adult Treatment Panel II report for men less than 45 yea rs of age and women less than 55 years of age who have elevations of LDL cholesterol in the 160 to 220 mg/dL range. They also may be recommended for clients with borderline high risk LDL levels and multiple risk factors for established coronary heart disease. Finally, the bile acid sequestrants are effective when they are combined with the statins (Iovastatin, pravastatin, simvastatin) for clients who exhibit severe hypercholesterolemia. The bile acid sequestrants are contraindicated as first line drugs for those clients with severe hypertriglyceridemia (grea ter than 500 mg/dL) because they may cause a rise in the triglyceride levels.
Cholestyramine and colestipol work by binding bile in the intestine, which produces a signal to the liver to produce more bile acids from cholesterol. A reduction of liver cholesterol content then stimulates formation of LDL receptors which allows a greater uptake of LDL from the blood. This interaction produces a reduced blood LDL level. Bile acid binding resins reduce LDL cholesterol concentration 15% to 30% depending upon the dosage.
Cholestyramine and colestipol are available in a powder or granule form which requires mixing with water or another substance. Pre- MARCH 1994, VOL. 42, NO.3 
Other Drugs
Gemfibrozil Probucol pared packets contain 5 gm colestipol or 4 gm of cholestyramine. They also are available in bulk form. A daily dose is divided between an a.m. and p.m. dose, with six packets or scoops considered a maximal dose. Because administration may be difficult for some clients, nurses can play an active role in early titration of these drugs. Normally clients begin with one packet or scoop daily, increasing this every 3 to 4 days until a desired dose is reached. Clients must remember to take these medications within 1 hour of a meal to obtain optimum drug effectiveness. The bile acid sequestrants are not without side effects. Nurses may help clients develop strategies for managing some of the most common side effects, which most often relate to the gastrointestinal system: constipation, abdominal cramps, heartburn, nausea, and bloating. A slow titration schedule helps minimize side effects. Because constipation often is the most troublesome side effect, increasing fluid intake, exercising, and using Metamucil are important techniques to help clients.
The bile acid sequestrants decrease the absorption of other medications. These medications include the thiazide diuretics, warfarin (Coumadin), digitalis, thyroxin, tetracycline, phenobarbitol, penicillin g, the beta blocking agents, and the fat soluble vitamins A, D, K, and E. For this reason, clients should take all other medications 1 hour before or 4 to 6 hours after the bile acid sequestrants.
Nicotinic acid (niacin) is a water soluble vitamin; used in high doses it can have a very favorable effect on lipoproteins. This drug may decrease LDL cholesterol 10% to 25%, increase high density lipoprotein (HDL) cholesterol 15% to Nurses in the occupational health care setting can playa significant role in helping clients manage their cholesterol lowering drugs. 35% , and decrease triglycerides 20% to 50%. Because of its favorable effect on the lipoprotein patterns, it is indicated in clients with moderately elevated LDL cholesterol levels combined with increased triglyceride and low HDL cholesterol levels. It also may be useful for clients with isolated low HDL cholesterol levels (less than 35 mg/dL) for whom drug therapy is indicated. Many clients with coronary heart disease who have borderline high LDL cholesterol levels and low HDL cholesterol levels can also benefit from nicotinic acid. Nicotinic acid acts primarily by reducing the production of very low density lipoprotein cholesterol (VLDL-C) by the liver. One of the main disadvantages of nicotinic acid is frequent, bothersome side effects. It may cause flushing or gastrointestinal symptoms such as nausea and dyspepsia, vomiting, and activation of peptic ulcer disease. Problems of hepatotoxicity, hyperuricemia and gout, and hyperglycemia also may occur. This drug must be used cautiously in clients with non-insulin dependent diabetes treated with oral hypoglycemic agents or with diet, as it may aggravate glucose control. Nurses can have a significant impact in helping clients to remain on nicotinic acid by suggesting strategies to deal with the side effects of flushing and gastrointestinal problems. Two of the main advantages of this drug are its low cost (approximately $6.44 per month for a 3 gm daily dose), and its effect on the lipoprotein patterns.
The HMGCoA reductase inhibitors (Iovastatin, pravastatin, and simvastatin) all lower LDL cholesterol, the prime target of therapy for most clients. These agents have similar efficacy when administered at the recommended times and dosages. They work by inhibiting the production of HMGCoA reductase, a rate limiting enzyme necessary for cholesterol production. They further stimulate LDL receptors, which promotes clearance of LDL from plasma.
The statins lower LDL cholesterol 20% to 40%, increase HDL cholesterol 5% to 15%, and decrease triglycerides 10% to 20%. For this reason, they are indicated in clients with high LDL cholesterol levels and those with severe hypercholesterolemia or established coronary heart dis-ease. Because their long term safety (beyond 5 years) has yet to be established, they are not the drug of first choice for young adults unless hypercholesterolemia is severe.
These drugs have several advantages. They are easily administered by pill in doses of 5 to 80 mg/day. Moreover, they have relatively few side effects. The most common side effects are gastrointestinal including dyspepsia, abdominal cramping, flatus, and constipation. In less than 1% of cases they may cause myopathy (muscle weakness), and increase creatine kinase values greater than 10 times normal limits. Clients are therefore requested to report muscle pain or weakness or brown urine, and creatine kinase measurements should be ordered to diagnose myopathy. Elevated liver transaminases may also occur in 1% to 2% of cases, especially if statins are prescribed at high doses. Therefore, liver transaminases should be tested at initiation of therapy and every 6 weeks for the first few months of therapy.
The fibric acid derivative, gemfibrozil, is used primarily to lower triglyceride levels, and to a lesser extent, increase HDL cholesterol. Triglycerides may decrease 20% to 50% and HDL cholesterol increase 10% to 15%. In clients whose lipid abnormality is high LDL cholesterol levels, gemfibrozil may reduce LDL cholesterol by 10% to 15%. However, in those with elevated triglycerides, LDL cholesterol may increase.
Certain new fibric acid derivatives (fenofibrate, bezafibrate, ciprofibrate), now available only in Europe, may have a more pronounced effect in lowering LDL cholesterol levels (Hunninghake, 1987; Illingworth, 1982) . Gemfibrozil is most often used in the treatment of very high triglycerides and in the primary prevention of coronary heart disease in clients with elevated LDL cholesterol levels, high triglycerides, and low HDL cholesterol levels without clinically evident coronary heart disease. It may be considered as a primary drug in clients with diabetes who have multiple lipid and lipoprotein abnormalities.
Like the statins, gemfibrozil is well tolerated. It is administered as a capsule, with normal dosage of 300 mg twice a day. Side effects most often include gastrointestinal complaints; however, the fibric acid derivative also may cause gallstones and liver toxicity.
The current role of probucol is difficult to define. It is an antioxidant that inhibits oxidation of LDL particles. Although LDL cholesterol is decreased 5% to 15% in clients taking probucol, it may also lower HDL cholesterol by 20% to 30%. Probucol is normally taken in 500 mg tablets twice a day with the morning and evening meal.
Side effects are infrequent but include gastrointestinal problems such as abdominal pain, flatulence, nausea and vomiting, prolongation of the QT interval, and, in some cases, ventricular arrhythmias. It is contraindicated in clients with cardiac arrhythmia with QT changes. Probucol is normally reserved for clients who have not tolerated or responded to other cholesterol lowering drugs.
CHOOSING AN APPROPRIATE DRUG
Because LDL cholesterol is the primary target in treating clients, the first priority is to choose a drug that lowers LDL cholesterol. The primary classes of drugs effective in lowering LDL cholesterol are the bile acid sequestrants and the statins. In addition, niacin is an effective drug to lower LDL cholesterol, especially if clients have low HDL levels. When choosing a cholesterol lowering agent, consideration must also be given to the efficacy of the drug, cost, compliance, side effects, clients' lifestyle patterns, and their preferences. Because many of the antihypertensive drugs can alter lipid levels, careful selection must be given to the use of these agents.
If LDL levels are significantly elevated, in many cases combination drug therapy will increase the effectiveness, lower the cost, increase compliance, and reduce side effects. For example, combining a bile sequestrant (8 gm of cholestyramine or 10 gm of colestipol) with a statin will reduce cholesterol by as much as 40% with less cost and side effects than using maximal dosages of either drug as a single therapy. Because the risk of myopathy increases when a statin is combined with gemfibrozil, this combination therapy should be avoided.
Cholesterol lowering can be seen in most clients after 4 to 6 weeks of starting drug therapy. Clients should have a repeat lipoprotein measurement 6 weeks after initiation of therapy to determine the effectiveness. A second measurement is indicated 6 weeks later. If target LDL cholesterol goals are met, clients are normally followed at 8 to 12 week intervals through the first year of therapy, and at 6 month intervals thereafter. Careful attention to blood chemistry measurements or toxicity of drugs is indicated.
FOLLOW UP: THE NURSE'S ROLE
Nurses in the occupational health care setting can play a significant role in helping clients manage their cholesterol lowering drugs. Clients need to be well educated about the drugs they are taking, including appropriate administration, dosages, side effects, what to do if doses are missed, and compliance techniques. As noted in the new guidelines (Expert Panel, 1993) , the MARCH 1994, VOL. 42, NO.3 
Help clients remember to take medication doses
Develop a reminder system with each client. Reminders can be setting alarm clocks to signal dosing times, using reminder cards placed in prominent places such as a refrigerator door, having spouses or friends remind clients of doses, and sending reminder cards for dosage refills.
Develop reinforcers of adherence
A powerful reinforcer allows a client to follow the outcome of therapy. Reviewing a chart of cholesterol measurements is a way to reinforce adherence.
Anticipate problems and teach clients to manage them
Teach the client problem solving skills. This can be accomplished by: identifying the problem, developing a plan for implementation, trying a solution, evaluating results, and repeating the process if initial solutions are not successful. Communication with a health care professional can be helpful in this process.
Involve a spouse or friend in the client's therapy
Encourage a spouse, family member, or friend to serve as a support person. This person can help provide another reminder for taking medications.
Make adherence important by asking about it
Periodically ask clients about medication taking to show concern. This can be accomplished by a simple question such as, "Most clients have difficulty remembering to take their medications. Do you ever miss a dose of your medication?" be detected 2 years after treatment (LRCI , 1991) , while in those with coronary heart disease, a slowing in progression or even regression of atherosclerosis can be seen after 2 years of aggressive therapy (Blanken horn, 1991) . If clients discontinue drugs, their cholesterol levels will return to pretreatment levels within a few weeks. Helping clients use techniques to adhere to life long therapy is of utmost importance in assuring adequate reduction in CHD events and potential slowing of the disease process. Occupational health nurses can use a variety of techniques , such as those listed in Table 2 , which include prompting, positive reinforcement, problem solving, and social support to help clients. These techniques are key to supporting clients in their efforts to manage the problem of hypercholesterolemia.
The National Cholesterol Education Program ATP II Report clearly defines those individuals most likely to benefit from drug therapy for treatment of cholesterol.
Knowing the choice of drugs, method of action, administration hints, and side effects of these agents is important for occupational health nurses.
The nurse's role in providing education, defining techniques to enhance compliance to medications , and reinforcing change in lifestyle behaviors is key to the client's success in maintaining life long therapy for cholesterol management.
1.
3.
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nurse's role is especially important in reinforcing and interpreting instructions provided by a primary provider. Assessment of side effects and compliance, including referral back to the primary care provider in case of problems, is an important role of the occupational health nurse. Clients who take cholesterol lowering drugs must not only understand that the agents are life long therapies, but must realize that maintaining a low fat , low cholesterol diet and exercise program, including weight loss if necessary, may lessen the need for higher doses of drugs. For this reason, reinforcement of these lifestyle behaviors is important.
In clients with high blood cholesterol, a reduction in coronary heart disease events can
